Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Fifth Third Bancorp ( FITB - Analyst Report ) has recently inked a deal to buy back about $125 million of its outstanding common stock. The share repurchase deal reached with Credit Suisse International, a division of Credit Suisse Group ( CS - Snapshot Report ) , is part of its capital plan that got the Federal Reserve’s nod in August this year and encompasses the repurchase of 100 million shares.
As per the agreement terms, Fifth Third will pay $125 million to Credit Suisse on November 9, 2012 and anticipates to receive a significant number of shares then. However, the final settlement for the actual number of shares that Fifth Third would receive is likely to occur on or before February 7, 2013.
The Back Story
As a matter of fact, though a number of Wall Street giants such as U.S. Bancorp ( USB - Analyst Report ) and Wells Fargo & Co. ( WFC - Analyst Report ) , passed the stress test earlier this year with their proposed capital plans, companies such as Fifth Third and Citigroup Inc. ( C - Analyst Report ) faced a setback as the Fed objected to their capital plans and these companies had to resubmit it again.
However, ushering in good news for the shareholders of Fifth Third, its revised capital plan through March 2013 received the Fed’s approval in August, which included a possible increase in its dividend in the third quarter as well as share buybacks. The approval justified the company’s capital strength.
Following this, the Board of Directors of Fifth Third approved a new share buyback authorization of 100 million shares. This replaced the previous authorization from 2007 that had 14 million shares remaining. The company had already bought back approximately 23 million shares for $350 million by October.
In addition to the positive development on the share buyback front, in September, Fifth Third also announced a 25% hike in its third quarter dividend on its common shares that increased to 10 cents per share from 8 cents paid earlier. The enhanced dividend was paid in October.
Our Take
The Fed’s objection to a number of elements in Fifth Third's capital plan, including increases in its quarterly common dividend and the initiation of common share repurchases, had put the company on the back foot and weakened its competitive position to some extent. Therefore, a positive development on that front is encouraging and this will inspire investors’ confidence in the stock.
Fifth Third currently retains its Zacks #3 Rank, which translates into a short-term Hold rating. Considering its fundamentals, we have a long-term Neutral recommendation on the stock.
Read the full reports :
Snapshot Report on CS
Analyst Report on FITB
Analyst Report on USB
Analyst Report on WFC
Analyst Report on C